DenmarkDenmark

Bavarian Nordic Receives US-Patent

06.08.2004

Copenhagen - Bavarian Nordic A/S has been recently issued a patent on its proprietary MVA-BN® technology by the United States Patent and Trademark Office which grants exclusive rights to the Danish company and claims MVA-BN® and derivatives thereof. Safety in humans continues to be the overriding challenge in vaccine development and production.
The patent grant to the MVA-BN virus, which is non-replicative in humans, acknowledges the novelty and utility of such a virus exhibiting the demonstrated safety profile of the MVA-BN technology and other claimed MVA viruses with similar characteristics. The patent includes the use of MVA-BN as a smallpox vaccine Imva-mune™, and extends to its use as a vector technology for developing recombinant vaccines against viral infectious diseases, such as HIV, Dengue Fever, Japanese Encephalitis. The patent covers the use of the MVA-BN technology in generating immunity in healthy and immune compromized subjects and inducing immunity through priming and boosting vaccination schedules. “With the issuance of this broad patent to the MVA-BN virus and its like acting derivatives, it will be difficult for others to develop and produce a safe and effective MVA-based vaccine without a license under this patent,” said CEO Peter Wulff.
The patent was followed by a fast track designation from the FDA for Imvamune, which will not impact the company's financial projections for 2004 of revenues of Euro18.8 million. Bavarian Nordic also entered into a collaboration on Imvamune with Glaxo-Smith-Kline (GSK) in July. GSK will manufacture and market the vaccine to international markets, including North and South America, Japan and a number of important EU-markets, including the UK and France. The Danish company will manufacture and market Imvamune to all German-speaking, Nordic and Baltic countries, China, the Middle East and South East Asia.

DenmarkDenmark

19.08.2011

Bagsværd – Net profit at Denmark’s Novo Nordisk A/S ballooned in the first six months of 2011, and the firm has raised guidance for the full year results. Sales rose by 9%, from DKK29.1bn to DKK31.7bn, while reported net profit...

DenmarkDenmark

15.08.2011

Copenhagen – Driven by strong sales, Danish drugmaker Lundbeck A/S reported hefty QII/2011 profits, and says it is now expecting full-year results at the upper end of its guided range. Operating profit rose to DKK1.1bn in the...

DenmarkDenmark

12.08.2011

Copenhagen - All is well in Denmark - for now. Danish Drugmaker Lundbeck reported excellent profits in the second quarter but announced its intention to prepare for deep cuts in research. 175 jobs in Denmark and the US (12.5% of...

DenmarkDenmark

06.06.2011

Kvistgaard – Bavarian Nordic A/S of Denmark has raised DKK698m (EUR94m)through a rights issue to fund development of its prostate cancer vaccine Prostvac. A total of 12.9 million shares were sold at DKK54. The company announced...

DenmarkDenmark

12.04.2011

Kvistgaard – Net loss at Danish biopharmaceutical company Bavarian Nordic A/S increased to DKK390m from DKK266m in the previous year, even though revenue grew to DKK314m, up from DKK75m in 2009. Bavarian Nordic’s lead product is...

DenmarkDenmark

09.04.2011

Copenhagen – Despite recent setbacks, Danish TopoTarget A/S still has hopes for its histone deacetylase (HDAc) blocker belinostat (PXD01). The cytotoxic compound for treating lymphoma and solid tumours has failed to show...

Displaying results 11 to 20 out of 194

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-denmark/browse/1/article/bavarian-nordic-receives-us-patent.html

Events

All Events

Stock list

All quotes

TOP

  • WILEX2.40 EUR6.67%
  • SANTHERA100.10 CHF1.78%
  • ACTELION112.70 CHF1.35%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • VITA 343.70 EUR-5.85%
  • EVOTEC3.68 EUR-1.60%

TOP

  • SANTHERA100.10 CHF67.1%
  • BB BIOTECH142.65 EUR10.2%
  • MAGFORCE6.80 EUR6.1%

FLOP

  • MOLOGEN7.31 EUR-14.0%
  • THERAMETRICS0.07 CHF-12.5%
  • VITA 343.70 EUR-11.1%

TOP

  • SANTHERA100.10 CHF4388.8%
  • CO.DON2.51 EUR213.7%
  • PAION2.43 EUR173.0%

FLOP

  • CYTOS0.25 CHF-93.7%
  • MEDIGENE4.53 EUR-67.5%
  • THERAMETRICS0.07 CHF-53.3%

No liability assumed, Date: 31.08.2014


Current issue

All issues

Product of the week

Products